Erratum: Retraction: MicroRNA-143 targets syndecan-1 to repress cell growth in melanoma(PLoS ONE(2014) 9:4(e94855) DOI: 10.1371/journal.pone.0094855);MicroRNA-143 targets syndecan-1 to repress cell growth in melanoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, Ruiya ^a   Zhang, Lingli ^a   Jia, Lizhou ^b   Duan, Yan ^a   Li, Yan ^b   Wang, Jie ^a   Bao, Lidao ^b   Sha, Na ^a  

^a Inner Mongolia Autonomous Region   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 143; SYNDECAN 1; MICRORNA; MIRN143 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MEMBRANE RECONSTITUTION; PATHOGENESIS; SKIN CANCER; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MICRORNAS; SKIN NEOPLASMS; SYNDECAN-1;

EID: 84899557005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0205767     Document Type: Erratum

References (33)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11-30.
2. Mimeault M, Batra SK (2012) Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol 3: 32-42.
3. Patel P M, Suciu S, Mortier L, Kruit WH, Robert C, et al. (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47: 1476-1483.
4. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355.
5. Gurtan AM, Sharp PA (2013) The role of miRNAs in regulating gene expression networks. J Mol Biol 425(19): 3582-3600.
6. MacRae I, Zhou K, Li F, Repic A, Brooks A, et al. (2006) Structural basis for double-stranded RNA processing by Dicer. Science 311(5758):195-198. (Pubitemid 43108178)
7. Li J, Lu X (2013) The emerging roles of 39 untranslated regions in cancer. Cancer Let 337(1):22-25.
8. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866. (Pubitemid 44629897)
9. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, et al. (2010) MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2:211-220.
10. Zhang Y, Wang Z, Chen M, Peng L, Wang X, et al. (2012) MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11:23.
11. Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, et al. (2013) MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci 9(7):680-692.
12. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. (Pubitemid 44629897)
13. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
14. Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E (2012) MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 33(10):1823-1832.
15. Fu X, Meng Z, Liang W, Tian Y, Wang X, et al. (2013) miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene doi: 10.1038/onc.2013.385.
16. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, et al. (2010) The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 5(11):e13779.
17. Noguchi S, Kumazaki M, Yasui Y, Mori T, Yamada N, et al. (2014) MicroRNA-203 Regulates Melanosome Transport and Tyrosinase Expression in Melanoma Cells by Targeting Kinesin Superfamily Protein 5b. J Invest Dermatol 134(2):461-9.
18. Manon-Jensen T, Itoh Y, Couchman JR (2010). Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277: 3876-3889.
19. Teng YH, Aquino RS, Park PW (2012) Molecular functions of syndecan-1 in disease. Matrix Biol 31: 3-16.
20. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, et al. (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280(10):2294-2306.
21. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67(1):11-18. (Pubitemid 39370345)
22. Yip GW, Smollich M, Götte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5: 2139-2148. (Pubitemid 44530449)
23. Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, et al. (2009) Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem 284(38):26085-26095.
24. Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, et al. (2004) Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 279: 8047-8055. (Pubitemid 38294693)
25. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291-3310. (Pubitemid 46763022)
26. Solus JF, Kraft S (2013) Ras, Raf, and MAP kinase in melanoma. Adv Anat Pathol 20(4):217-226.
27. Xu B, Niu X, Zhang X, Tao J, Wu D, et al. (2011) miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350(1-2):207-213.
28. Lai VK, Ashraf M, Jiang S, Haider K (2012) MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 11(4):767-777.
29. Wu N, Sulpice E, Obeid P, Benzina S, Kermarrec F, et al. (2012) The miR-17 family links p63 protein to MAPK signaling to promote the onset of human keratinocyte differentiation. PLoS One 7(9):e45761.
30. Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, et al. (2012) Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells. PLoS One 7(10):e48091.
31. Sun H, Hu Y, Gu Z, Owens RT, Chen YQ, et al. (2011) Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis 32(10): 1518-1524.
32. Sethi S, Ali S, Philip PA, Sarkar FH (2013) Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci 14(7):14771-14784.
33. Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E (2012) MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 33(10):1823-1832.